Quick Takeaways
- Cambridge Equities, LP filed SCHEDULE 13D/A for ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX).
- Disclosed ownership: 66%.
- Date of event: 23 Feb 2026.
Quoteable Key Fact
"Cambridge Equities, LP disclosed 66% ownership in ImmunityBio, Inc. Common Stock, par value $0.0001 per share (IBRX) on 23 Feb 2026."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Cambridge Equities, LP | 26% | 261,705,814 | 0 | 261,705,814 | /s/ Charles Kenworthy | Charles Kenworthy, Manager of MP 13 Ventures, LLC, the General Partner of Cambridge Equities, LP | 0001629222 |
| MP 13 Ventures, LLC | 26% | 261,705,814 | 0 | 261,705,814 | /s/ Charles Kenworthy | Charles Kenworthy, Manager | 0001629186 |
| NantWorks, LLC | 9.6% | 98,535,253 | 0 | 98,535,253 | /s/ Robert Morse | Robert Morse, CFO of NantWorks, LLC | 0001675760 |
| Nant Capital, LLC | 30% | 339,465,529 | 0 | 339,465,529 | /s/ Charles Kenworthy | Charles Kenworthy, Manager of Nant Capital, LLC | 0001675758 |
| California Capital Equity, LLC | 10% | 106,511,412 | 0 | 106,511,412 | /s/ Charles Kenworthy | Charles Kenworthy, Manager of California Capital Equity, LLC | 0001517764 |
| Patrick Soon-Shiong | 66% | 745,576,456 | 32,275,375 | 713,301,081 | /s/ Patrick Soon-Shiong | Patrick Soon-Shiong | 0001189020 |